279 related articles for article (PubMed ID: 28889106)
1. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.
Wedzicha JA; Calverley PMA; Albert RK; Anzueto A; Criner GJ; Hurst JR; Miravitlles M; Papi A; Rabe KF; Rigau D; Sliwinski P; Tonia T; Vestbo J; Wilson KC; Krishnan JA
Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889106
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.
Nici L; Mammen MJ; Charbek E; Alexander PE; Au DH; Boyd CM; Criner GJ; Donaldson GC; Dreher M; Fan VS; Gershon AS; Han MK; Krishnan JA; Martinez FJ; Meek PM; Morgan M; Polkey MI; Puhan MA; Sadatsafavi M; Sin DD; Washko GR; Wedzicha JA; Aaron SD
Am J Respir Crit Care Med; 2020 May; 201(9):e56-e69. PubMed ID: 32283960
[No Abstract] [Full Text] [Related]
3. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.
Wedzicha JA; Miravitlles M; Hurst JR; Calverley PM; Albert RK; Anzueto A; Criner GJ; Papi A; Rabe KF; Rigau D; Sliwinski P; Tonia T; Vestbo J; Wilson KC; Krishnan JA
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28298398
[TBL] [Abstract][Full Text] [Related]
4. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
[TBL] [Abstract][Full Text] [Related]
5. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
8. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline.
Chalmers JD; Laska IF; Franssen FME; Janssens W; Pavord I; Rigau D; McDonnell MJ; Roche N; Sin DD; Stolz D; Suissa S; Wedzicha J; Miravitlles M
Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32366483
[TBL] [Abstract][Full Text] [Related]
9. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
10. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
12. Chronic obstructive pulmonary disease--a treatable disease.
Osthoff M; Jenkins C; Leuppi J
Swiss Med Wkly; 2013; 143():w13777. PubMed ID: 23592218
[TBL] [Abstract][Full Text] [Related]
13. [Phosphodiesterase-4 inhibitors: roflumilast].
Izquierdo Alonso JL
Rev Clin Esp; 2011 Mar; 211 Suppl 2():22-30. PubMed ID: 21596170
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
[TBL] [Abstract][Full Text] [Related]
15. Clinical Question: In adults with COPD does roflumilast reduce the frequency of exacerbations compDared to standard therapies aIone?
Huser JM; Hodgden JD
J Okla State Med Assoc; 2016 Feb; 109(2):59-60. PubMed ID: 27169222
[No Abstract] [Full Text] [Related]
16. Clinical Considerations for Roflumilast: A New Treatment for COPD.
Kelly Freeman ML
Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
[TBL] [Abstract][Full Text] [Related]
17. [Clinical profile of roflumilast].
Izquierdo Alonso JL
Arch Bronconeumol; 2010 Dec; 46 Suppl 10():25-32. PubMed ID: 21316553
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA
Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847
[TBL] [Abstract][Full Text] [Related]
19. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.
Giembycz MA; Newton R
Clin Chest Med; 2014 Mar; 35(1):203-17. PubMed ID: 24507847
[TBL] [Abstract][Full Text] [Related]
20. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.
Holguin F; Cardet JC; Chung KF; Diver S; Ferreira DS; Fitzpatrick A; Gaga M; Kellermeyer L; Khurana S; Knight S; McDonald VM; Morgan RL; Ortega VE; Rigau D; Subbarao P; Tonia T; Adcock IM; Bleecker ER; Brightling C; Boulet LP; Cabana M; Castro M; Chanez P; Custovic A; Djukanovic R; Frey U; Frankemölle B; Gibson P; Hamerlijnck D; Jarjour N; Konno S; Shen H; Vitary C; Bush A
Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31558662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
